NASDAQ:EWTX Edgewise Therapeutics (EWTX) Stock Forecast, Price & News $9.51 -0.19 (-1.96%) (As of 12:39 PM ET) Add Compare Share Share Today's Range$9.45▼$9.6550-Day Range$5.71▼$10.1252-Week Range$5.53▼$14.33Volume22,775 shsAverage Volume168,326 shsMarket Capitalization$601.78 millionP/E RatioN/ADividend YieldN/APrice Target$17.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Edgewise Therapeutics MarketRank™ ForecastAnalyst RatingHold2.33 Rating ScoreUpside/Downside78.8% Upside$17.00 Price TargetShort InterestBearish11.33% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingSelling Shares$101,789 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($1.66) to ($2.02) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.56 out of 5 starsMedical Sector855th out of 980 stocksPharmaceutical Preparations Industry428th out of 485 stocks 3.2 Analyst's Opinion Consensus RatingEdgewise Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 2 buy ratings, no hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $17.00, Edgewise Therapeutics has a forecasted upside of 78.8% from its current price of $9.51.Amount of Analyst CoverageEdgewise Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted11.33% of the float of Edgewise Therapeutics has been sold short.Short Interest Ratio / Days to CoverEdgewise Therapeutics has a short interest ratio ("days to cover") of 25.8, which indicates bearish sentiment.Change versus previous monthShort interest in Edgewise Therapeutics has recently increased by 1.81%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldEdgewise Therapeutics does not currently pay a dividend.Dividend GrowthEdgewise Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for EWTX. Previous Next 2.0 News and Social Media Coverage News SentimentEdgewise Therapeutics has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Edgewise Therapeutics this week, compared to 1 article on an average week. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Edgewise Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $101,789.00 in company stock.Percentage Held by Insiders37.05% of the stock of Edgewise Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Edgewise Therapeutics are expected to decrease in the coming year, from ($1.66) to ($2.02) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Edgewise Therapeutics is -7.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Edgewise Therapeutics is -7.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEdgewise Therapeutics has a P/B Ratio of 1.74. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Edgewise Therapeutics (NASDAQ:EWTX) StockEdgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial. It develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.Read More Receive EWTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Edgewise Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address EWTX Stock News HeadlinesJune 1, 2023 | americanbankingnews.comEdgewise Therapeutics (NASDAQ:EWTX) Shares Down 5.6% May 17, 2023 | americanbankingnews.comWedbush Comments on Edgewise Therapeutics, Inc.'s Q1 2024 Earnings (NASDAQ:EWTX)June 5, 2023 | Edge On The Street (Ad)Investor Alert: EV Initiatives Create Unsustainable Demand For LithiumThe soaring demand for lithium is driven by worldwide demand for electric vehicles (EVs). Lithium is ideal for electric cars. It's lightweight, stores lots of energy and is rechargeable. Sales of EVs are expected to increase 10-fold by 2030 and estimates are that 1 in 2 cars sold will be electric by 2040.May 16, 2023 | msn.comJP Morgan Maintains Edgewise Therapeutics (EWTX) Overweight RecommendationMay 12, 2023 | msn.comWedbush Reiterates Edgewise Therapeutics (EWTX) Outperform RecommendationMay 12, 2023 | markets.businessinsider.comRBC Capital Reaffirms Their Buy Rating on Edgewise Therapeutics (EWTX)May 11, 2023 | msn.comEdgewise Therapeutics: Q1 Earnings InsightsMay 6, 2023 | americanbankingnews.comInsider Selling: Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Insider Sells $15,548.30 in StockJune 5, 2023 | Edge On The Street (Ad)New "Mined in America" Lithium Opportunities?The average electric vehicle needs 138 pounds of lithium carbonate for its battery components. But China currently controls the entire lithium supply chain.May 6, 2023 | americanbankingnews.comInsider Selling: Edgewise Therapeutics, Inc. (NASDAQ:EWTX) CFO Sells $11,890.40 in StockMay 6, 2023 | americanbankingnews.comEdgewise Therapeutics, Inc. (NASDAQ:EWTX) CMO Joanne M. Donovan Sells 3,254 SharesMay 6, 2023 | americanbankingnews.comEdgewise Therapeutics, Inc. (NASDAQ:EWTX) CEO Sells $28,506.70 in StockMay 5, 2023 | americanbankingnews.comJohn R. Moore Sells 1,897 Shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX) StockMay 1, 2023 | markets.businessinsider.comFlexing On Muscular Dystrophy, Analyst Expects Almost 200% Upside For Edgewise TherapeuticsMay 1, 2023 | msn.comBenzinga's Top Ratings Upgrades, Downgrades For May 1, 2023May 1, 2023 | msn.comTruist Securities Initiates Coverage of Edgewise Therapeutics (EWTX) with Buy RecommendationMay 1, 2023 | americanbankingnews.comEdgewise Therapeutics (NASDAQ:EWTX) Now Covered by Analysts at Truist FinancialMarch 30, 2023 | finance.yahoo.comEdgewise Therapeutics Announces Journal of Clinical Investigation Publication of Key Preclinical Data Linking Modulation of Fast Skeletal Muscle Contraction to Protection of Skeletal Muscle in Models of Duchenne Muscular Dystrophy (DMD)March 21, 2023 | finance.yahoo.comEdgewise Therapeutics to Present at the Stifel 2023 CNS Days on March 28, 2023March 14, 2023 | finance.yahoo.comEdgewise Therapeutics to Present on EDG-5506 for Becker and Duchenne Muscular Dystrophy (BMD, DMD) at the 2023 Annual MDA Clinical and Scientific ConferenceMarch 6, 2023 | finance.yahoo.comEdgewise Therapeutics Appoints Industry Veteran Jonathan C. Fox, M.D., Ph.D., FACC to its Board of DirectorsMarch 1, 2023 | finance.yahoo.comEdgewise Therapeutics to Present at the Cowen 43rd Annual Health Care Conference on March 8, 2023February 28, 2023 | finance.yahoo.comEdgewise Therapeutics Announces Upcoming Presentation at the American College of Cardiology's 72nd Annual Scientific Session Together with World Congress of CardiologyFebruary 28, 2023 | markets.businessinsider.comRBC Capital Sticks to Their Buy Rating for Edgewise Therapeutics (EWTX)February 23, 2023 | msn.comEdgewise Therapeutics GAAP EPS of -$0.31 beats by $0.05February 7, 2023 | finance.yahoo.comEdgewise Therapeutics to Present at the SVB Securities Global Biopharma Conference on February 14, 2023January 4, 2023 | finance.yahoo.comEdgewise Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023See More Headlines EWTX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart EWTX Company Calendar Last Earnings11/10/2021Today6/05/2023Next Earnings (Estimated)8/03/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:EWTX CUSIPN/A CIK1710072 Webwww.edgewisetx.com Phone720-262-7002FaxN/AEmployees31Year FoundedN/APrice Target and Rating Average Stock Price Forecast$17.00 High Stock Price Forecast$29.00 Low Stock Price Forecast$5.00 Forecasted Upside/Downside+78.8%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.33) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-67,640,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-23.63% Return on Assets-22.50% Debt Debt-to-Equity RatioN/A Current Ratio26.22 Quick Ratio26.22 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.48 per share Price / Book1.74Miscellaneous Outstanding Shares63,279,000Free Float43,061,000Market Cap$601.78 million OptionableNot Optionable Beta-0.13 Key ExecutivesDr. Kevin Koch Ph.D. (Age 63)Pres, CEO & Director Comp: $845.33kDr. Badreddin Edris Ph.D. (Age 36)Co-Founder & Independent Director Comp: $36.26kDr. Behrad Derakhshan Ph.D. (Age 43)Chief Bus. Officer Comp: $575.53kDr. Joanne M. Donovan M.D. (Age 66)Ph.D., Chief Medical Officer Comp: $556.23kDr. Alan J. Russell Ph.D. (Age 53)Co-Founder, Chief Scientific Officer & Director Mr. R. Michael Carruthers (Age 65)Chief Financial Officer Mr. John R. Moore (Age 59)Gen. Counsel Dr. Marc Semigran M.D. (Age 66)Chief Devel. Officer More ExecutivesKey CompetitorsGeneluxNASDAQ:GNLXHarrow HealthNASDAQ:HROWSeres TherapeuticsNASDAQ:MCRB2seventy bioNASDAQ:TSVTTerns PharmaceuticalsNASDAQ:TERNView All CompetitorsInsiders & InstitutionsJPMorgan Chase & Co.Bought 7,063 shares on 5/18/2023Ownership: 0.050%New York State Common Retirement FundSold 10,731 shares on 5/18/2023Ownership: 0.021%Geode Capital Management LLCBought 53,342 shares on 5/16/2023Ownership: 1.226%Susquehanna International Group LLPBought 16,885 shares on 5/16/2023Ownership: 0.027%Balyasny Asset Management L.P.Sold 3,100 shares on 5/16/2023Ownership: 0.024%View All Insider TransactionsView All Institutional Transactions EWTX Stock - Frequently Asked Questions Should I buy or sell Edgewise Therapeutics stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Edgewise Therapeutics in the last year. There are currently 1 sell rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" EWTX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EWTX, but not buy additional shares or sell existing shares. View EWTX analyst ratings or view top-rated stocks. What is Edgewise Therapeutics' stock price forecast for 2023? 3 analysts have issued twelve-month price targets for Edgewise Therapeutics' stock. Their EWTX share price forecasts range from $5.00 to $29.00. On average, they predict the company's stock price to reach $17.00 in the next twelve months. This suggests a possible upside of 78.8% from the stock's current price. View analysts price targets for EWTX or view top-rated stocks among Wall Street analysts. How have EWTX shares performed in 2023? Edgewise Therapeutics' stock was trading at $8.94 at the start of the year. Since then, EWTX stock has increased by 6.4% and is now trading at $9.51. View the best growth stocks for 2023 here. When is Edgewise Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023. View our EWTX earnings forecast. How were Edgewise Therapeutics' earnings last quarter? Edgewise Therapeutics, Inc. (NASDAQ:EWTX) posted its earnings results on Wednesday, November, 10th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by $0.05. What ETFs hold Edgewise Therapeutics' stock? ETFs with the largest weight of Edgewise Therapeutics (NASDAQ:EWTX) stock in their portfolio include Virtus LifeSci Biotech Clinical Trials ETF (BBC), iShares Neuroscience and Healthcare ETF (IBRN), ALPS Medical Breakthroughs ETF (SBIO), Principal Healthcare Innovators ETF (BTEC), Invesco Nasdaq Biotechnology ETF (IBBQ), iShares Biotechnology ETF (IBB), ProShares Ultra Nasdaq Biotechnology (BIB) and When did Edgewise Therapeutics IPO? (EWTX) raised $150 million in an initial public offering on Friday, March 26th 2021. The company issued 10,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs, SVB Leerink and Wedbush PacGrow acted as the underwriters for the IPO. What is Edgewise Therapeutics' stock symbol? Edgewise Therapeutics trades on the NASDAQ under the ticker symbol "EWTX." Who are Edgewise Therapeutics' major shareholders? Edgewise Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include FMR LLC (12.55%), BlackRock Inc. (4.54%), Geode Capital Management LLC (1.23%), Granahan Investment Management LLC (1.16%), State Street Corp (1.04%) and American Century Companies Inc. (0.80%). Insiders that own company stock include Alan J Russell, Behrad Derakhshan, Holdings A/S Novo, James E Flynn, Joanne M Donovan, John R Moore, Jonathan D Root, Kevin Koch, Orbimed Advisors Llc, Peter A Thompson and R Michael Carruthers. View institutional ownership trends. How do I buy shares of Edgewise Therapeutics? Shares of EWTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Edgewise Therapeutics' stock price today? One share of EWTX stock can currently be purchased for approximately $9.51. How much money does Edgewise Therapeutics make? Edgewise Therapeutics (NASDAQ:EWTX) has a market capitalization of $601.78 million. The company earns $-67,640,000.00 in net income (profit) each year or ($1.33) on an earnings per share basis. How can I contact Edgewise Therapeutics? Edgewise Therapeutics' mailing address is 3415 COLORADO AVE., BOULDER CO, 80303. The official website for the company is www.edgewisetx.com. The company can be reached via phone at 720-262-7002 or via email at ir@edgewisetx.com. This page (NASDAQ:EWTX) was last updated on 6/5/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Edgewise Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.